EX-99.1 2 abbv-20230930nonxgaapxex991.htm EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended September 30, 2023																		Full-Year Ended December 31, 2023
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q3 2023 acquired IPR&D and milestones expense			$	—					$	2.80					$	2.90					$	430					$	10.90					$	11.10
Q3 2023 acquired IPR&D and milestones expense			66						(0.04)						(0.04)						66						(0.04)						(0.04)
Guidance including Q3 2023 acquired IPR&D and milestones expensea			$	66					$	2.76					$	2.86					$	496					$	10.86					$	11.06

a    The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2023, as both cannot be reliably forecasted.

    1